新闻动态 2022.09.071298

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Radiobiology and Nuclear Medicine".

Deadline for manuscript submissions: 31 December 2022

Special Issue Editors


Special Issue Information

Dear Colleagues,

Cancer is the first or second most common cause of death. Unfortunately, in the next 50 years, the global number of cancer patients is expected to rise. In this sense, there is a need for more effective and selective therapies. Boron neutron capture therapy (BNCT) is a very promising tumor-selective particle radiotherapy. It involves the preferential accumulation of boron carriers in tumor cells, followed by irradiation with a thermal or epithermal neutron beam. Overall BNCT clinical results to date show therapeutic efficacy, associated with an improvement in patient quality of life and prolonged survival. Radiobiological BNCT studies have been of utmost importance to make progress in BNCT, which are also essential to design novel, safe, and effective clinical BNCT protocols (https://isnct.net/).


The aim of this Special Issue is to collect the latest BNCT radiobiological findings performed in in vivo and in vitro experimental models. We also encourage the authors to submit their latest results in the BNCT clinical veterinary field. Contributions should be related to, but not limited to, the study of BNCT for different pathologies, BNCT combined with other cancer therapies, findings related to the radiobiological mechanisms induced by BNCT, the evaluation of new boron compounds, and strategies that could enhance BNCT therapeutic effect and reduce toxicity. We encourage authors to contribute radiobiological findings in the more recently developed area of accelerator based-BNCT, but of course also welcome contributions in the well-established area of reactor-based BNCT.    


Looking forward to receiving many valuable contributions.


Dr. Andrea Monti Hughes
Dr. Silva Bortolussi
Dr. Amanda Schwint

Guest Editors


Manuscript Submission Information


Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.


Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.


Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.



  • boron neutron capture therapy

  • particle therapy

  • radiobiology

  • experimental studies

  • clinical veterinary studies